

2nd World Conference on

Targeting Liver Diseases

Sciences, Clinical Innovations & Biotechnology

June 25 - 26, 2015 - St Julian's, Malta

Second World Conference on

Targeting Liver Diseases

Sciences, Clinical Innovations & Biotechnology

June 25-26, 2015 – Saint Julian's, Malta

Final Agenda

www.targeting-liver.com

GENERAL INFORMATION

DATE

June 25-26, 2015

CITY/COUNTRY

St Julian, Malta

CONFERENCE VENUE

Radisson Blu St Julian Resort

St. George's Bay – STJ3391

St Julian's, Malta

REGISTRATION & PRACTICAL INFORMATION

Targeting Liver Diseases 2015 Secretary

Tel: +33 1 55 04 77 55

Fax: +33 9 72 16 84 14

Email: liver@targeting-liver.com



2nd World Conference on
Targeting Liver Diseases

Sciences, Clinical Innovations & Biotechnology

June 25-26, 2015 – Saint Julian's, Malta

After the success of the first edition held on June 2014 in Jerusalem, it is a great pleasure to announce you the organization of the **Second World Conference on Targeting Liver Diseases: Science, Clinical Innovations & Biotechnology** to be held in St Julian's, Malta in June 25-26, 2015.

Targeting Liver Diseases 2015 is not just another liver meeting to update in liver progress. However, we are a creating a kind of mind storming forum to create a new therapeutic approaches that are targeting the liver. Not only liver research and topics are proposed, but also other important research that is easing up a liver benefit. It could be research tools in other fields that implicate liver research, or important non liver pathways that are potential to be helpful in a future liver research, etc.

Therefore, Targeting Liver Diseases 2015 is including also non liver topics to be exposed for the liver researchers to enrich knowledge. The same with the clinical and basic science combination that are coming to feed each side more proximity and leading to more focused research based on real needs. During Targeting Liver 2015, we will initiate new channels and fields such as Microbiota, Stem Cells, Mitochondria and wave them to liver homeostasis and pathologies.

Targeting Liver Diseases 2015 will be divided on two days:

Day 1: Targeting Liver Diseases 2015: Recent Advances & Perspectives

- *Liver Diseases & Primary Sclerosing Cholangitis*
- *Liver Diseases & Cancer*
- *Liver Diseases, Oxidative Stress, Mitochondria & Microbiota*
- *Liver Diseases & Endotoxins*
- *Liver Transplantation*
- *Liver Diseases & Fibrosis*
- *Fatty Liver Diseases*
- *Liver Diseases & Viral Infection*
- *Liver Diseases & Stem Cells*

Day 2: Targeting Liver Diseases 2015: The Innovations

Malta Liver 2015: New Targets and Therapies in Liver Diseases

Malta Liver 2015 will provide a unique and rare opportunity for interactions between industry and liver disease experts. Seeking to help identify unmet needs in hepatology, these 2 days will look toward the future to determine how to address the long-term challenges that hepatologists are likely to face in the coming years.

We look forward welcoming you in beautiful St Julian's.

Prof. Marvin Edeas - Prof. Rifaat Safadi
Chairmen of the Scientific Committee



Targeting Liver Diseases

Sciences, Clinical Innovations and Biotechnology

June 25-26, 2015 - St Julian's, Malta

Day 1 – June 25, 2015

08h00 Registration of Attendees

09h00 Welcome Note by the Chairmen of the Scientific Committee
Marvin Edeas, Rifaat Safadi

09h10 Targeting Liver Diseases 2015: What we should know?
Rifaat Safadi, Hadassah Hebrew University Medical Center, Israel

Session 1: Targeting Liver Diseases 2015: Recent Advances & Perspectives (Part 1)

Chairmen: Roger Chapman & Marvin Edeas

Liver Diseases & Primary Sclerosing Cholangitis

09h35 Pathogenesis and Management of Primary Sclerosing Cholangitis
Roger Chapman, John Radcliffe Hospital, United Kingdom

Liver Diseases & Cancer

10h00 Rewiring Metabolism in Liver Cancer: A Story of a Large Gene
Rami Aqeilan, Hadassah Hebrew University Medical Center, Israel

10h25 Coffee Break & Posters Session

10h55 Senescence-Related Gene Signatures as Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma
Mehmet Ozturk, Dokuz Eylül University, Turkey

11h20 Detection of HCC-derived DNA Markers in Urine for HCC Screening
Ying-Hsiu Su, Baruch S. Blumberg Institute, USA

Liver Diseases, Oxidative Stress, Mitochondria & Microbiota *Strategies to overcome liver dysfunctions by antioxidants*

11h35 Mitochondria & Microbiota: The Intriguing Relationship
Marvin Edeas, Chairman of Targeting Mitochondria Task Force, France

12h00 Alcohol Abuse, Oxidative Stress, Nucleoredoxin and Hepatic fibrogenesis: Role of Polyphenols
Raj Lakshman, George Washington University, USA

12h25 Lunch Break & Posters Session

Chairmen: Rami Aqeilan & Rifaat Safadi

14h00 Microbiota & Liver Diseases: A Mouse Model of Alcoholic Liver Disease Reveals Protection by *Lactobacillus Fermentum*
Antonella Marino Gammazza, University of Palermo, Italy

14h25 Treatment with SRT1720, A Sirt1 Allosteric Activator, Ameliorates D-Galactosamine/Lipopolysaccharide- Induced Hepatotoxicity
Mighty Kemelo, Charles University in Prague, Czech Republic

Liver Diseases & Endotoxins

14h35 Targeting Endotoxins and Cytokines in Liver Diseases

Jens Hartmann, Danube University Krems, Austria

Liver Diseases & Fibrosis

15h00 An Adverse Outcome Pathway from Protein Alkylation to Liver Fibrosis

Brigitte Landesmann, European Commission, Institute of Health and Consumer Protection, Italy

15h25 Coffee Break & Posters Session

Chairmen: Raj Lakshman & Mehmet Ozturk

Fatty Liver Diseases

15h55 Mapping Host Genetic Determinants Underlying the Development of Fatty Liver Diseases: The Collaborative Cross Mice to the Rescue

Fuad Iraqi, Tel Aviv University, Israel

Alcoholic Fatty Liver Diseases

16h20 HCV & Acetaldehyde deregulate interferon signaling in liver cells by impairing methylation reactions

Natalia A. Osna, University of Nebraska Medical Centre, USA

16h45 Short Oral Presentations upon Abstract Submission (5 + 2 minutes)

Cytoplasmic RNA Sensor Rig-I Dually Mediates Antiviral Activities during HBV Infection

Akinori Takaoka, Hokkaido University, Japan

Bergamot Polyphenol Fraction Prevents Non-Alcoholic Fatty Liver Disease Via Stimulation of Lipophagy in Cafeteria Diet – Induced Rat Model Of Metabolic Syndrome.

Elzbieta Jand, Health Sciences Magna Graecia University

Treating Cholangitis with Mitochondrial Medicine

Rainer Mutschler, BioMedical Center Speyer, Germany

Inhibition of Neutral Sphingomyelinase Decreases Elevated Levels of Nitrate and Oxidative Stress Markers in Liver Ischemia–Reperfusion Injury

Mutay Aslan, Akdeniz University Faculty of Medicine, Turkey

Predictive Models with Liver Cancer Multiple Measurements Data Based on Support Vector Machines: A Case Study

Feipei Lai, National Taiwan University, Taiwan

Serum Selenium (SSE) in Hemodialysis Treated Patients (HDTP) without Liver Disease (Ld) or With Liver Cirrhosis (LC).

Diana Hristova Yonova, Medical University, Sofia, Bulgaria

Targeting Cell Cycle in Liver Tumors

Kasim M. Diril, Izmir Biomedicine and Genome Institute, Turkey

Autophagy & Apoptosis in Hepatic Stellate Cell and MAPK Pathway Regulate Them

Yuanwei Pan, University of Traditional Medicine, China

Enos Polymorphisms in Relation to Outcome in Advanced HCC Patients Receiving Sorafenib Final Result of Ephas Study

Giorgia Marisi, IRST-IRCCS, Italy

High Cholesterol Diet as a Trigger for Green Tea Extract-Induced Liver Injury

Zecharia Madar, Hebrew University, Israel

Advanced Human in Vitro Models for the Study of Cholestasis

Fozia Noor, Saarland University, Germany

Relationship between Serum Concentrations of Bile Acids and Obese Patients with Type 2 Diabetes
Libor Vitek, Charles University in Prague, Czech Republic

Carotenoid Receptor and Intrahepatic Delivery
Ivan Petyaev, Lycotec Ltd, United Kingdom

18h15 End of First Day

20h00 **Targeting Liver Diseases Dinner with Speakers & Participants**
To participate to this dinner, you have to register online before June 20.

Day 2 – June 26, 2015

08h55 Opening of the Second Day

Session 1: Targeting Liver Diseases 2015: Recent Advances & Perspectives (Part 2)

Chairmen: Matthias Bartneck & Wladimiro Jimenez

Liver Diseases & Stem Cells

09h00 **Direct Reprogramming and its Potential Implications for the Treatment of Liver Diseases**
Amar Deep Sharma, Hannover Medical School, Germany

Part 2: Liver Diseases 2015: The Innovations

09h25 **Liver Diseases & Drug Development: What's New?**
The new HCV therapies: A revolution in the liver medicine
Rifaat Safadi, Hadassah Hebrew University Medical Center, Israel

09h50 **Therapeutic Targeting of Liver Inflammation and Fibrosis by Nanomedicine**
Matthias Bartneck, RWTH-University Hospital Aachen, Germany

10h15 **Cerium Oxide Nanoparticles in Liver Disease: Therapeutic Usefulness in Experimental Models of Liver Fibrosis**
Wladimiro Jimenez, University of Barcelone, Spain

10h40 Coffee Break & Posters Session

11h10 **Inhibition of Pannexin1 Channels Alleviates Acetaminophen-Induced Hepatotoxicity**
Mathieu Vinken, Vrije Universiteit Brussel Laarbeeklaan, Belgium

11h35 **Effective Multiple Oral Administration of Reverse Genetics Engineered Infectious Bursal Diseases Virus in Mice in the Presence of Neutralizing Antibodies**
Tibor Bakacs, HepC Ltd, Hungary

12h00 **Extracorporeal Liver Support – A Balancing Act between Efficiency and Biocompatibility**
Stephan Harm, Danube University Krems, Austria

12h25 **Discussion & Conclusion of Targeting Liver Diseases 2015 Conference**
Targeting Liver Diseases 2015 Scientific Awards

13h00 End of Targeting Liver Diseases 2015 Conference

13h00 Lunch Break